Results 21 to 30 of about 60,579 (143)

Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome

open access: yesCase Reports in Immunology, 2019
Hyper-IgE syndrome (HIES) is a rare primary immunodeficiency characterized by elevated levels of immunoglobulin E (IgE), eczematous dermatitis, cold abscesses, and recurrent infections of the lung and skin caused by Staphylococcus aureus.
Cesar Daniel Alonso-Bello   +10 more
doaj   +1 more source

Monoclonal antibodies: their place in applied medicine and their role in the newest infectious disease – history, present, and future. Literature review [PDF]

open access: yesPharmacia
Monoclonal antibodies (mAbs) are immunoglobulins with practically absolute specificity (monospecificity) for a particular antigen (epitope). Over the past three decades, monoclonal antibodies have undergone a remarkable transformation, evolving from ...
Petar Yordanov Atanasov   +11 more
doaj   +3 more sources

Development of a humanized anti-FABP4 monoclonal antibody for potential treatment of breast cancer

open access: yesBreast Cancer Research
Background Breast cancer is the most common cancer in women diagnosed in the U.S. and worldwide. Obesity increases breast cancer risk without clear underlying molecular mechanisms.
Jiaqing Hao   +9 more
doaj   +1 more source

New targeted treatments for cutaneous T-cell Lymphomas

open access: yesIndian Journal of Dermatology, 2017
Cutaneous T-cell lymphomas (CTCLs) represent a group of rare and heterogeneous diseases that are very difficult to treat at advanced stages. The development of monoclonal antibodies is a new hope for the treatment of these diseases. Alemtuzumab (Campath)
Martine Bagot
doaj   +1 more source

Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity

open access: yesEmerging Microbes and Infections, 2020
Coronaviruses cause severe human viral diseases including SARS, MERS and COVID-19. Most recently SARS-CoV-2 virus (causing COVID-19) has led to a pandemic with no successful therapeutics.
Jianbo Dong   +6 more
doaj   +1 more source

Current status of skin cancers with a focus on immunology and immunotherapy

open access: yesCancer Cell International, 2023
Skin cancer is one of the most widespread cancers, with a significant global health effect. UV-induced DNA damage in skin cells triggers them to grow and proliferate out of control, resulting in cancer development. Two common types of skin cancer include
Mahsa Khayyati Kohnehshahri   +6 more
doaj   +1 more source

An Overview of Off-Label Use of Humanized Monoclonal Antibodies in Paediatrics

open access: yesMedicina, 2022
In recent years, off-label and unlicensed drug use has extensively developed in the paediatric population. For a long time, clinical trials in the paediatric population were considered complicated to perform because of ethical problems, causing frequent ...
Roberto Bernardini   +2 more
doaj   +1 more source

Physiologically‐based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2022
Intravenous immunoglobulin (IVIG) (2000 mg/kg) increased the clearance of the mouse monoclonal antibody 7E3, directed against platelet integrin IIb/IIIa (alpha IIb beta 3, CD41/CD61) in rodents. We wanted to investigate the effect of IVIG on clearance of
Sara N. Salerno   +2 more
doaj   +1 more source

Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies

open access: yesFrontiers in Immunology, 2022
Management of refractory immune thrombocytopenia frequently involves rituximab, a chimeric anti-CD20 monoclonal antibody, to target B cells and induce remission in most patients.
Jennifer R. Blase   +3 more
doaj   +1 more source

Role of Monoclonal Antibodies in the Treatment of Asthma

open access: yesCanadian Respiratory Journal, 2013
BACKGROUND: Patients with severe refractory asthma represent a small subset of the asthmatic population (between 5% and 10% of all patients) but are the greatest burden to the health care system.
Paul M O’Byrne
doaj   +1 more source

Home - About - Disclaimer - Privacy